Azenta Inc. shares fell as much as 10.4% on Monday, dropping to an intraday low of $31.90 from a prior close of $37.40, following the immediate resignation of Chief Executive John Marotta.
The decline extended losses from May 2026 lows, where the stock had previously more than doubled. The Nasdaq Composite slipped 0.7% during the same session. The company confirmed a one-time consulting charge of approximately $3 million in the fourth quarter, which will impact adjusted EBITDA. Total revenue guidance for the quarter was reaffirmed despite the leadership disruption and additional expense.
Marotta, who had served as CEO, president, and board member, stepped down with immediate effect. The board appointed Dr. Martin Madaus as interim CEO and board member. Madaus, a Senior Operating Executive at The Carlyle Group with over 30 years of experience in life sciences tools and diagnostics, will oversee the transition. Heidrick & Struggles was engaged to conduct an executive search for a permanent replacement.
Azenta’s stock had surged earlier this year, recovering from multi-year lows in May 2026. The rapid ascent prompted at least one analyst to warn of a potential reversal, though the company has not revised its financial outlook. The shares remain sensitive to leadership changes and operational guidance amid broader market conditions.
